QIAGEN adds biopharma products to QIAcuity digital PCR portfolio

Image credit: www.qiagen.com

QIAGEN has announced a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers, particularly those involved in the biopharma industry.

• New solutions are now available with ten new QIAcuity Cell and Gene Therapy (CGT) dPCR Assays for use in adeno-associated virus (AAV) titer quantification and three new QIAcuity Residual DNA Quantification Kits for checking carryover of host cell DNA.
• A new version of the QIAcuity Software Suite has been released with expanded functionality to support good manufacturing practice (GMP) compliance.

The major expansion of QIAGEN’s dPCR assay offerings comes after a milestone was achieved with more than 1,000 cumulative placements of the QIAcuity system since launch in late 2020. QIAcuity’s approach to digital PCR is based on using nanoplates to partition the samples more quickly than other systems. The instruments – available in one, four and eight-plate versions – integrate partitioning, thermocycling and imaging into one workflow, cutting processing times to only two hours from six.